Skip to search formSkip to main contentSkip to account menu

ametantrone

Known as: 9, 10-Anthracenedione, 1, 4-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-, HAQ, 1,4-bis[[2-[(2-Hydroxyethyl)amino]ethyl]amino]9,10-anthracenedione 
A topoisomerase II inhibitor of the anthrapyrazole family that causes covalent cross-links in DNA of tumor cells.
National Institutes of Health

Related topics

Related topics

9 relations
Ametantrone AcetateDNA Breaks, Double-StrandedDNA IntercalationNCIt Antineoplastic Agent Terminology

Broader (3)

Antineoplastic AgentsIntercalating AgentsMitoxantrone

Narrower (1)

NSC 287513

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus…
Objectives Tumour necrosis factor inhibition plus methotrexate is believed to inhibit radiographic progression independent of… 
Highly Cited
2010
Highly Cited
2010
Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial.
OBJECTIVES To characterize the baseline tendon friction rubs (TFRs) in early dcSSc and to evaluate the association of change in… 
2008
2008
Synthesis, DNA binding, and cytotoxicity of 1,4-bis(2-amino-ethylamino)anthraquinone-amino acid conjugates.
Highly Cited
2005
Highly Cited
2005
Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure.
OBJECTIVE To assess the efficacy and safety of the fully human recombinant monoclonal anti-TNF antibody adalimumab in routine… 
2005
2005
Human telomerase inhibition and cytotoxicity of regioisomeric disubstituted amidoanthraquinones and aminoanthraquinones.
Highly Cited
2002
Highly Cited
2002
The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database.
OBJECTIVE A primary therapeutic goal in rheumatoid arthritis (RA) is to reduce functional disability. The recent introduction of… 
2002
2002
Functional impairment in spondyloarthropathy and fibromyalgia.
OBJECTIVE To compare the functional ability of patients with spondyloarthropathy (SpA) and fibromyalgia (FM) using the Bath… 
Highly Cited
1991
Highly Cited
1991
A comparison of disability measured by the Stanford Health Assessment Questionnaire disability scales (HAQ) in male and female rheumatoid outpatients.
Eighty-five consecutive rheumatoid patients (M:F = 22:63) seen during a 10-week period were studied. There were significant… 
Highly Cited
1983
Highly Cited
1983
Bis(alkylamino)anthracenedione antineoplastic agent metabolic activation by NADPH-cytochrome P-450 reductase and NADH dehydrogenase: diminished activity relative to anthracyclines.
Highly Cited
1981
Highly Cited
1981
Comparative structure-genotoxicity study of three aminoanthraquinone drugs and doxorubicin.
Two aminoanthraquinone analogs 1,4-bis(2-[(2-hydroxyethyl)amino]ethylamino)-9,10-anthracenedione (HAQ) and 1,4-dihydroxy-5,8-bis… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)